AstraZeneca: new approval for Lynparza in breast cancer
(CercleFinance.com) - The US Food and Drug Administration has approved PARP inhibitor Lynparza to treat metastatic breast cancer, AstraZeneca and partner Merck said over the weekend.
The drug is now the only PARP inhibitor approved beyond ovarian cancer, both drugmakers said.
In a Phase III trial, Lynparza reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy.
AstraZeneca and Merck said they are now working to deliver the drug as quickly as possible to more patients in other indications, including prostate and pancreatic cancers.
Under the oncology collaboration with Merck, AstraZeneca will receive 70 million dollars in revenue after this approval.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The drug is now the only PARP inhibitor approved beyond ovarian cancer, both drugmakers said.
In a Phase III trial, Lynparza reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy.
AstraZeneca and Merck said they are now working to deliver the drug as quickly as possible to more patients in other indications, including prostate and pancreatic cancers.
Under the oncology collaboration with Merck, AstraZeneca will receive 70 million dollars in revenue after this approval.
Copyright (c) 2018 CercleFinance.com. All rights reserved.